Trial NCT04642638
Publication Mammen Jr M, medRxiv, 2021
Primary outcome on the report: The primary endpoints for the Phase 2 segment were immunologic in nature and comprised antigen-specific cellular immune responses measured by IFN-γ ELISpot assay and neutralizing antibody responses as measured by a pseudovirus-based neutralization assay.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.